MiMedx Retained Earnings (Accumulated Deficit) 2010-2024 | MDXG

MiMedx retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

MiMedx Retained Earnings (Accumulated Deficit) 2010-2024 | MDXG

MiMedx retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$172.8B
Vertex Pharmaceuticals (VRTX)$125.8B
Regeneron Pharmaceuticals (REGN)$111.1B
Bristol Myers Squibb (BMY)$108.2B
Gilead Sciences (GILD)$108B
CSL (CSLLY)$97B
GSK (GSK)$81.3B
Alnylam Pharmaceuticals (ALNY)$38.6B
Argenex SE (ARGX)$32.3B
BioNTech SE (BNTX)$28B
Biogen (BIIB)$27.5B
Illumina (ILMN)$22.9B
Moderna (MRNA)$22.1B
BeiGene (BGNE)$21.6B
Genmab (GMAB)$15B
BioMarin Pharmaceutical (BMRN)$13.3B
Insmed (INSM)$13.2B
Vaxcyte (PCVX)$13.2B
Exact Sciences (EXAS)$13B
Incyte (INCY)$12.7B
Sarepta Therapeutics (SRPT)$12B
Bio-Techne Corp (TECH)$11.4B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.9B
Revolution Medicines (RVMD)$8.4B
Exelixis (EXEL)$8.4B
Intra-Cellular Therapies (ITCI)$8B
Legend Biotech (LEGN)$8B
Ascendis Pharma (ASND)$7.9B